[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ventricular-arrhythmia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ventricular-arrhythmia":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,13,0,[8,54,86,111,138,164,198,227,258,288,318,341,387],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":29,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":53},"100641518","prospective-multicentre-observational-registry-of-peri-procedural-anaesthesia-sedation-and-related-medication-exposure-in-patients-with-brugada-syndrome-100641518",false,"NCT07655102","Prospective Multicentre Observational Registry of Peri-procedural Anaesthesia, Sedation and Related Medication Exposure in Patients With Brugada Syndrome","BRUGADA-ANAESTHESIA Registry: Prospective Multicentre Observational Registry of Peri-procedural Anaesthesia, Sedation and Related Medication Exposure in Patients With Brugada Syndrome","PROSP_BRUGANAE","Patients should match all the inclusion criteria to be entered for data collection:\n\n* Documented type 1 Brugada ECG pattern (spontaneous, fever-related, or induced by sodium-channel blocker challenge\u002Fother recognised provocation test) with a diagnosis considered compatible with Brugada syndrome by the treating cardiology team.\n* Undergoing general anaesthesia, monitored sedation, loco-regional anaesthesia for any surgical, diagnostic, interventional, obstetric or other non-surgical procedure (including epidural analgesia for labour and sedation for endoscopy).\n\nPatients with one or more exclusion criteria will not be included for data collection and analysis:\n\n* No documented type 1 Brugada ECG pattern, uncertain diagnosis without sufficient supporting data.\n* Refusal to participate in the study.","ALL",{"count":19,"type":20},200,"ESTIMATED","30 Days","OBSERVATIONAL","The goal of this observational study is to evaluate the perioperative risk of malignant ventricular arrhythmias in adult patients diagnosed with Brugada Syndrome undergoing anaesthetic procedures. Brugada Syndrome is a rare inherited cardiac condition associated with an increased risk of life-threatening arrhythmias, and perioperative management remains challenging due to limited high-quality evidence.\n\nThe main questions it aims to answer are:\n\n* What is the incidence of malignant ventricular arrhythmias during anaesthesia and up to 30 days after the procedure?\n* Are anaesthetic drugs traditionally considered \"non-recommended\" associated with an increased risk of perioperative arrhythmic events?\n\nResearchers will also explore the relative contribution of anaesthetic drugs versus perioperative physiological factors (e.g., haemodynamic changes, fever, bradycardia) in triggering arrhythmias.\n\nParticipants will:\n\n* Undergo anaesthetic procedures (general, locoregional, or sedation) as part of routine clinical care\n* Have clinical data collected prospectively from electronic medical records during the perioperative period\n* Be followed for 30 days after the procedure to assess outcomes, including arrhythmias, complications, ICU admission, and mortality\n\nThis is a multicentre, prospective observational registry, and no additional interventions or changes to standard clinical practice will be performed.",[25,26,27,28],"Brugada Syndrome (BrS)","Ventricular Arrhythmia","Anesthesia","Sedation",[30,31,27,32,33,34,35,36,37,38,39,40],"Brugada Syndrome","Anaesthesia","Perioperative Care","Ventricular Arrhythmias","Cardiac Arrhythmias","Perioperative Risk","Anesthetic Drugs","Propofol","Sodium Channel Blockers","Observational Registry","Multicentre Study","NOT_YET_RECRUITING","2026-06-12",{"date":44,"type":45},"2026-06-17","ACTUAL",{"date":47,"type":20},"2026-07-20",{"date":49,"type":20},"2028-12-20",{"name":51,"class":52},"Hospital Clinic of Barcelona","OTHER",1,{"id":55,"slug":56,"hasResults":11,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":60,"eligibilityCriteria":61,"healthyVolunteers":11,"sex":17,"minAge":62,"maxAge":4,"enrollmentInfo":63,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":65,"conditions":66,"keywords":68,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":85},"100632733","ventricular-arrhythmias-in-acute-myocardial-infarction-100632733","NCT07517523","Ventricular Arrhythmias in Acute Myocardial Infarction","Ventricular Arrhythmias in the Acute Phase of Myocardial Infarction: ADVERSE MI Study","ADVERSE-MI","Inclusion Criteria:\n\n* ≥ 18 years\n* Acute myocardial infarction\n* Sustained ventricular arrhythmia (ventricular tachycardia or ventricular fibrillation) at the acute phase of an acute myocardial infarction (before hospital discharge)\n* Between January 1, 2012 and April 14, 2024\n\nExclusion Criteria:\n\n* None","18 Years",{"count":64,"type":20},500,"Ventricular arrhythmias are a serious complication of myocardial infarction. The aim of this study is to provide reliable data on the management and mortality associated with ventricular arrhythmia in the setting of acute myocardial infarction.",[26,67],"Acute Myocardial Infarction (AMI)",[69,70,71,72,73,74],"ST-segment elevation myocardial infarction","non-ST-segment elevation myocardial infarction","ventricular fibrillation","ventricular tachycardia","cardiac arrest","implantable cardioverter defibrillator","RECRUITING","2026-05-26",{"date":78,"type":45},"2026-05-28",{"date":80,"type":45},"2025-06-20",{"date":82,"type":20},"2027-10-01",{"name":84,"class":52},"Poitiers University Hospital",8,{"id":87,"slug":88,"hasResults":11,"nctId":89,"briefTitle":90,"officialTitle":91,"acronym":92,"eligibilityCriteria":93,"healthyVolunteers":11,"sex":17,"minAge":62,"maxAge":4,"enrollmentInfo":94,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":96,"conditions":97,"keywords":99,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":4},"100631499","arrhythmic-risk-in-myocarditis-outcome-research-100631499","NCT07501481","Arrhythmic Risk in Myocarditis Outcome Research","Incidence, Clinical Impact, and Prediction of Ventricular Arrhythmia in Patients With Acute Myocarditis","ARMOR","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Hospitalization for acute myocarditis\n* Confirmation of the diagnosis of AM by at least one of the following: (1) Cardiac magnetic resonance according to the revised 2018 Lake Louise Criteria; (2) Endomyocardial biopsy according to the Dallas criteria with associated immunohistochemical and molecular criteria; (3) Cardiac computed tomography with compatible late iodine enhancement\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years\n* Concomitant acute coronary syndrome",{"count":95,"type":20},1500,"The goal of this observational, retrospective, multicenter study is to characterize the arrhythmic burden and identify predictive factors for ventricular arrhythmias (VAs) in adult patients hospitalized for acute myocarditis (AM). The main questions it aims to answer are:\n\n* What is the incidence of sustained ventricular arrhythmias during the index hospitalization in patients with acute myocarditis?\n* What clinical, biological, electrocardiographic, and imaging factors predict the occurrence of sustained ventricular arrhythmias during hospitalization and after discharge?\n\nResearchers will compare patients who developed sustained VAs during hospitalization to those who did not, in order to identify independent predictors of arrhythmic events and develop a validated risk stratification score.\n\nParticipants' medical records from 2020 to 2024 will be reviewed to collect:\n\n* Baseline demographic, clinical, biological, electrocardiographic, and imaging data at admission\n* In-hospital management strategies and outcomes, including mortality, cardiogenic shock, and heart replacement therapy\n* Long-term follow-up data including VA recurrence, sudden cardiac death, and development of cardiomyopathy, with censoring applied on January 1, 2026",[98,26],"Myocarditis Acute",[100,101,72,71],"acute myocarditis","ventricular arrhythmia","2026-03-26",{"date":104,"type":45},"2026-03-30",{"date":106,"type":20},"2026-03-01",{"date":108,"type":20},"2027-03-31",{"name":110,"class":52},"AZ Sint-Jan AV",{"id":112,"slug":113,"hasResults":11,"nctId":114,"briefTitle":115,"officialTitle":116,"acronym":117,"eligibilityCriteria":118,"healthyVolunteers":11,"sex":17,"minAge":62,"maxAge":4,"enrollmentInfo":119,"targetDuration":4,"studyType":121,"phases":122,"briefSummary":124,"conditions":125,"keywords":4,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":137},"100608434","real-time-intracardiac-echocardiography-for-ventricular-arrhythmia-ablation-100608434","NCT07201506","Real-Time Intracardiac Echocardiography for Ventricular Arrhythmia Ablation","Real-Time Intracardiac Echocardiography for Ventricular Arrhythmia Ablation: A Randomized Controlled Trial","REAL-ICE","Inclusion Criteria:\n\n* Patients (≥18y) undergoing a premature ventricular contraction or ventricular tachycardia ablation.\n\nExclusion Criteria:\n\n* Origin of ventricular arrhythmia with high likelihood in the right ventricular outflow tract (left-bundle-inferior axis, \\>V4 transition precordially)\n* Primary epicardial ablation planned\n* Congenital heart disease\n* Presence of a mechanical tricuspid valve prosthesis\n* Unwilling or unable to comply fully with study procedures and followup",{"count":120,"type":20},70,"INTERVENTIONAL",[123],"NA","This study is investigating whether using ultrasound directly inside the heart during ablation of heart rhythm disorders in the ventricles can reduce radiation exposure for patients.\n\nDuring an ablation, catheters are guided through the heart to treat the abnormal electrical signals. Usually, X-ray imaging (fluoroscopy) is used to see where the catheters are, which exposes both patients and hospital staff to radiation.\n\nThe study is randomized and controlled: half of the participants will have the ablation with ultrasound inside the heart, and the other half will have the standard ablation without ultrasound during the procedure. The main goal is to compare the amount of X-ray time used during the procedure. Secondary goals are to look at safety, effectiveness, and the total procedure time.\n\nPatients with premature ventricular contractions or ventricular tachycardia can take part. A total of 70 people will be included, 35 in each group. Using ultrasound inside the heart makes it possible to see the catheters and heart structures directly, so many steps can be done without X-rays. This could make ablations safer and reduce radiation exposure.\n\nThe study is being carried out at Inselspital, Bern University Hospital, and at University Hospital Basel. All steps are standardized and data are collected carefully. The results will show whether ultrasound during ablations can significantly reduce radiation and make ablations more efficient and safer.",[126,127,128,26],"Ablation of Arrhythmias","Premature Ventricular Contractions","Ventricular Tachycardia",{"date":130,"type":45},"2026-04-01",{"date":132,"type":45},"2026-03-25",{"date":134,"type":20},"2027-06-30",{"name":136,"class":52},"Insel Gruppe AG, University Hospital Bern",2,{"id":139,"slug":140,"hasResults":11,"nctId":141,"briefTitle":142,"officialTitle":143,"acronym":4,"eligibilityCriteria":144,"healthyVolunteers":11,"sex":17,"minAge":62,"maxAge":4,"enrollmentInfo":145,"targetDuration":4,"studyType":121,"phases":147,"briefSummary":149,"conditions":150,"keywords":153,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":156,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":162,"locationsCount":53},"100609191","phase-4-percutaneous-blockade-of-the-stellate-ganglion-in-electrical-storm-100609191","NCT07211347","Percutaneous Blockade of the Stellate Ganglion in Electrical Storm","Percutaneous Blockade Protocol of the Stellate Ganglion in Patients With Refractory Electrical Storm","Inclusion Criteria:\n\n* Patients over 18 years old with structural heart disease and a diagnosis of refractory electrical storm, or those who require discontinuation of antiarrhythmics due to adverse events or contraindications to standard therapy.\n\nExclusion Criteria:\n\n* Patients under 18\n* History of heart transplant or prior cardiac denervation surgery\n* Anatomical contraindications for the procedure (prior neck surgery, burns, large scars, or thyroid goiter).\n* Genetically related polymorphic VT\n* End-stage renal disease on dialysis",{"count":146,"type":20},64,[148],"PHASE4","There is no randomized clinical study in the literature that evaluated the efficacy and safety of the stellate ganglion infiltration procedure in patients with electrical storm. So far, case reports and retrospective studies suggest that such a strategy should be considered in cases refractory to initial therapy. In this scenario, the European and American guidelines for the treatment of ventricular arrhythmias recommend autonomic modulation in this setting, but only with a level of recommendation IIb (1,2). This project aims to evaluate the effect of stellate ganglion infiltration in patients with electric storm refractory to initial clinical measures. It is a randomized clinical trial where patients will receive treatment with a lidocaine and bupivacaine anesthetic solution or no intervention. The effect of the intervention will be considered positive when there is a reduction of arrhythmic events of at least 50% in the 12 hours immediately after.",[151,152,26],"Electrical Storm","Stellate Ganglion Block",[26,151,154],"Stellate ganglion block","2025-09-29",{"date":157,"type":45},"2025-10-07",{"date":159,"type":45},"2025-06-06",{"date":161,"type":20},"2028-12",{"name":163,"class":52},"University of Sao Paulo General Hospital",{"id":165,"slug":166,"hasResults":11,"nctId":167,"briefTitle":168,"officialTitle":168,"acronym":169,"eligibilityCriteria":170,"healthyVolunteers":11,"sex":17,"minAge":62,"maxAge":4,"enrollmentInfo":171,"targetDuration":4,"studyType":121,"phases":173,"briefSummary":174,"conditions":175,"keywords":181,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":189,"lastUpdatePostDateStruct":190,"startDateStruct":192,"completionDateStruct":194,"leadSponsor":196,"locationsCount":5},"100590211","phase-4-comparative-effectiveness-of-carvedilol-versus-metoprolol-succinate-in-heart-failure-patients-with-an-implantable-cardioverter-defibrillator-100590211","NCT06964464","Comparative Effectiveness of Carvedilol Versus Metoprolol Succinate in Heart Failure Patients With an Implantable Cardioverter Defibrillator","CARVTOP-ICD","Inclusion Criteria:\n\n* Age ≥ 18 years\n* ICD implanted for primary prevention for HFrEF (either ICM or NICM) with remote monitoring capability\n* Current treatment with metoprolol succinate and willing to switch to carvedilol\n* LVEF \\\u003C50% during the past 12 months prior to consent\n\nExclusion Criteria:\n\n* Unwilling or unable to follow the protocol\n* Treatment with any other ßB than metoprolol succinate or no ßB treatment\n* Known prior intolerance or contraindication to carvedilol\n* Systolic blood pressure \\\u003C100 mmHg\n* Enrollment in another clinical trial\n* Inability or unwilling to consent",{"count":172,"type":20},2000,[148],"This prospective, multicenter, open-label, randomized comparative effectiveness trial, titled CARVTOP-ICD, evaluates the impact of carvedilol versus metoprolol succinate in patients with heart failure with reduced ejection fraction (HFrEF) and an implantable cardioverter defibrillator (ICD). The study will enroll 2,000 participants across 100 U.S. sites and includes an 18-month feasibility phase with 100 participants from 15 sites. Eligible participants must be currently treated with metoprolol succinate and willing to switch to carvedilol, with randomization in a 1:1 ratio. Participants will be followed for up to 3 years, with regular assessments including ICD interrogations, medication adherence, healthcare utilization, and quality of life surveys. The primary endpoint is the first occurrence of any ICD therapy (appropriate or inappropriate), cardiovascular (CV) hospitalization, or CV death. Secondary endpoints include ICD shock burden, healthcare utilization, and patient-reported quality of life. The trial aims to provide high-quality comparative data to address clinical equipoise surrounding the two commonly used beta-blockers in HFrEF management.",[176,177,26,178,179,180],"Heart Failure With Reduced Ejection Fraction (HFrEF)","Sudden Cardiac Death","Implantable Cardioverter Defibrillator (ICD)","Beta-blocker Therapy","Cardiomyopathy",[182,183,184,74,185,186,187,188],"arrhythmia","heart failure","ICD","ICD shock","carvedilol","metoprolol succinate","beta-blocker","2025-09-12",{"date":191,"type":45},"2025-09-18",{"date":193,"type":45},"2025-08-17",{"date":195,"type":20},"2031-07-01",{"name":197,"class":52},"University of Rochester",{"id":199,"slug":200,"hasResults":11,"nctId":201,"briefTitle":202,"officialTitle":202,"acronym":203,"eligibilityCriteria":204,"healthyVolunteers":11,"sex":17,"minAge":62,"maxAge":205,"enrollmentInfo":206,"targetDuration":4,"studyType":121,"phases":208,"briefSummary":209,"conditions":210,"keywords":213,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":217,"lastUpdatePostDateStruct":218,"startDateStruct":220,"completionDateStruct":222,"leadSponsor":224,"locationsCount":226},"100594534","electrophysiological-characterization-of-the-arrhythmia-substrate-for-sudden-cardiac-death-prediction-100594534","NCT07020702","ElectroPhySiological Characterization Of the Arrhythmia Substrate for Sudden Cardiac Death PrEdiction","EP-SCOPE","Inclusion Criteria:\n\n* Patient with cardiomyopathy with 35%\\\u003CLVEF\\\u003C50% and at least one risk factor\n* Patients with cardiomyopathy with LVEF≤35% and an indication for cardiac resynchronisation\n\nExclusion Criteria:\n\n* Patients who are minors or aged 80 or over\n* Patients with unstable coronary artery disease\n* Myocardial infarction less than 40 days old\n* Coronary revascularisation \\\u003C90 days\n* Patients with intracardiac thrombus\n* Patients with a mechanical heart valve\n* Patient implanted with an automatic defibrillator\n* Patient life expectancy \\\u003C1 year\n* Pregnant or breast-feeding women\n* Anti-arrhythmic drugs other than beta-blockers and amiodarone","80 Years",{"count":207,"type":20},210,[123],"EP-SCOPE is a prospective, multicentric, non-randomized pilot study that aims to estimate the risk of life-threatening ventricular arrhythmia through use of advanced electrophysiological studies in patients with ischemic or non-ischemic cardiomyopathy with left ventricular ejection fraction (LVEF) \\\u003C50% and risk factors of ventricular arrhythmia, otherwise not considered for implantation of an implantable cardioverter defibrillator (ICD).\n\nThe objective is to assess the effectiveness of a risk stratification strategy based on detailed electrophysiological exploration of the left ventricle and programmed ventricular stimulation.",[26,211,212],"Cardiomyopathies","Left Ventricular Ejection Fraction Less Then or Equal to 50percent",[214,215,216],"cardiomyopathies","sudden death","Myocardial Infarction","2025-07-07",{"date":219,"type":45},"2025-07-10",{"date":221,"type":45},"2023-06-12",{"date":223,"type":20},"2030-09-12",{"name":225,"class":52},"University Hospital, Bordeaux",3,{"id":228,"slug":229,"hasResults":11,"nctId":230,"briefTitle":231,"officialTitle":232,"acronym":233,"eligibilityCriteria":234,"healthyVolunteers":235,"sex":17,"minAge":62,"maxAge":4,"enrollmentInfo":236,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":238,"conditions":239,"keywords":244,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":249,"lastUpdatePostDateStruct":250,"startDateStruct":252,"completionDateStruct":254,"leadSponsor":256,"locationsCount":53},"100594064","using-heart-electrical-signals-to-study-how-well-treatments-prevent-dangerous-heart-rhythms-in-active-people-100594064","NCT07014579","Using Heart Electrical Signals to Study How Well Treatments Prevent Dangerous Heart Rhythms in Active People","Utilizing LifeMap To Investigate Malignant Arrhythmia Therapeutic Efficacy in Athletes","ULTIMATE-A","Inclusion Criteria:\n\n* Age 18 and over.\n* Participates in regular physical activity for at least 3 hours or greater weekly.\n* Having Implantable cardioverter defibrillator insitu (cases).\n* Having a cardiac pacemaker (control).\n* Having no cardiac device (control).\n* Sufficient capacity and agreement to participate orally and signed written consent forms.\n* Understanding of written and spoken English language.\n\nExclusion Criteria:\n\n* Pregnancy, as detected by positive urine pregnancy test result.\n* Inability to comply with study protocols.\n* Any iatrogenic cardiac pathology (stents, CABG etc).\n* Unstable ventricular tachycardia (\\>30 seconds).\n* Any unstable malignant arrhythmia.\n* Fever or presence of a clinically diagnosed febrile illness",true,{"count":237,"type":20},40,"The goal of this observational study is to learn if two specific heart electrical signal patterns can help in detecting the risk of dangerous heart rhythms in athletes, and to see if exercise-based tests can be used instead of invasive hospital procedures to record this electrical signals.\n\nThe main questions it aims to answer are:\n\n1. Can special ECG action potential duration markers (R2I2 and PERS) identify athletes who are at higher risk of sudden heart rhythm problems.\n2. Can an exercise test give the same information as a non-invasive electrophysiology study.\n\nResearchers will compare athletes who have an implanted heart device (ICD) with athletes who do not, to see if there are differences in these heart signals.\n\nParticipants will undergo:\n\n1. ECG recordings during rest and exercise.\n2. If they have an ICD or pacemaker, an ECG will be recorded during a non invasive stimulation.\n3. A continuous 24 hour ECG.",[240,241,26,242,243],"Inherited Cardiac Conditions","Sudden Cardiac Arrest","Athlete","Ventricular Fibrillation",[245,246,247,248,26,243,177],"ULTIMATE-Athlete","LifeMap","R2I2","PERS","2025-06-09",{"date":251,"type":45},"2025-06-11",{"date":253,"type":20},"2025-06-01",{"date":255,"type":20},"2026-07-31",{"name":257,"class":52},"University of Leicester",{"id":259,"slug":260,"hasResults":11,"nctId":261,"briefTitle":262,"officialTitle":263,"acronym":264,"eligibilityCriteria":265,"healthyVolunteers":11,"sex":17,"minAge":266,"maxAge":4,"enrollmentInfo":267,"targetDuration":4,"studyType":121,"phases":269,"briefSummary":270,"conditions":271,"keywords":273,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":279,"lastUpdatePostDateStruct":280,"startDateStruct":282,"completionDateStruct":284,"leadSponsor":286,"locationsCount":53},"100575220","proton-radiosurgery-for-the-treatment-of-malignant-ventricular-tachyarrhythmias-100575220","NCT06769451","Proton Radiosurgery for the Treatment of Malignant Ventricular Tachyarrhythmias","Radiosurgery With proTOns for the Treatment of VEntricular maLignant Tachyarrhytmias (TOVEL Study)","TOVEL","Inclusion Criteria:\n\n1. age ≥ 40 years\n2. carrier of ICD\u002FCRT-D or S-ICD\n3. episodes of ventricular tachycardia\u002Fventricular fibrillation requiring defibrillator intervention (shock or ATP) which are:\n\n   * refractory to maximal drug therapy;\n   * recurrent (at least 3 episodes in the previous 6 months);\n4. patients with contraindications to a conventional ablative strategy, in relation to the high risk associated with the procedure due to the severity of the heart disease and\u002For the presence of comorbidities or patients who have already undergone ablation, in the presence of an arrhythmogenic substrate refractory to or unsuitable for an interventional approach or patients who refuse transcatheter ablative attempts due to high intraoperative risk in relation to the patient's characteristics.\n5. Left ventricular ejection fraction ≥ 20%.\n\nExclusion Criteria:\n\n1. inability to express informed consent\n2. previous thoracic radiotherapy (RT) with cardiac involvement\n3. active myocardial ischemia\n4. recent cardiac revascularization (\\\u003C 120 days)\n5. hemodynamic instability (cardiogenic shock, NYHA class IV)\n6. contraindication to radiosurgery (e.g., due to artifacts or other technical reasons)\n7. lack of patient cooperation in pre-procedural investigations\n8. ICD malfunction\n9. severe comorbidity with prognosis \\\u003C 12 months\n10. pregnancy","40 Years",{"count":268,"type":20},21,[123],"Ventricular arrhythmias (VAs) are the leading cause of sudden cardiac death (SCD) worldwide. The implantable defibrillator (ICD) increases survival in patients at risk of VA, with data of superiority to antiarrhythmic drugs. Nevertheless, the ICD cannot prevent VAs, and shocks delivered by the device (appropriate and inappropriate) negatively impact patients' quality of life. Transcatheter ablation (TCA) is the percutaneous therapy that can eliminate VAs and prevent any recurrence. TCA is the state of the art for the treatment of drug-unresponsive VAs in patients with structural heart disease, but the prevalence of recurrence remains high (between 30% and 60%). For these reasons, several reports have recently appeared in the literature proposing a new solution for the treatment of VAs in which the use of external-beam body radiotherapy with stereotactic-radiosurgical technique (SBRT) is described. SBRT represents a rapid, noninvasive approach based on the delivery of high radiation doses of photons (25 Gy in a single fraction) to a precise location in cardiac tissue.\n\nSBRT has entered the latest 2022 European Society of Cardiology (ESC) guidelines on VAs as a \"bailout therapy\". Based on preliminary data in the oncology setting, proton therapy could allow further optimization of compliance of these therapeutic doses by preserving even more of the healthy heart part and thus reducing the cardiopulmonary toxicity of radiotherapy outside the ablation target.\n\nThe investigators therefore propose an experimental (prospective interventional) study to evaluate the toxicity (primary endpoint) and efficacy (secondary endpoint) of proton radiosurgery for the treatment of VA with an enrollment of 21 patients. The primary endpoint is to evaluate the toxicity of proton radiotherapy in the acute phase (during the first 30 days of the procedure) and at 3, 6 and 12 months. A crucial part of the protocol will be the proper definition of the target to be irradiated, which will require the integration of different non-invasive cardiac imaging methodologies such as CT (Computed Tomography), MRI (Magnetic Resonance Imaging) and PET (Positron Emission Tomography), coupled with invasive and\u002For \"non-invasive\" body surface mapping with multi-electrode electrocardiogram (ECG) so as to obtain a \"cardiac image\" in which the myocardial scar and the arrhythmogenic region are fused.",[26,272],"Ventricular Tachycardia (V-Tach)",[274,275,276,277,278],"Stereotactic arrhythmia radioablation (STAR)","Malignant ventricular Tachycardia","Ventricular Tachycardia Storm","Radiotherapy","Proton Therapy","2025-01-23",{"date":281,"type":45},"2025-01-27",{"date":283,"type":20},"2025-02",{"date":285,"type":20},"2030-02",{"name":287,"class":52},"Azienda Sanitaria Universitaria Integrata del Trentino",{"id":289,"slug":290,"hasResults":11,"nctId":291,"briefTitle":292,"officialTitle":293,"acronym":294,"eligibilityCriteria":295,"healthyVolunteers":11,"sex":17,"minAge":62,"maxAge":4,"enrollmentInfo":296,"targetDuration":297,"studyType":22,"phases":4,"briefSummary":298,"conditions":299,"keywords":303,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":308,"lastUpdatePostDateStruct":309,"startDateStruct":311,"completionDateStruct":313,"leadSponsor":315,"locationsCount":317},"100572222","image-based-prediction-of-ventricular-tachycardia-events-in-non-ischemic-cardiomyopathy-100572222","NCT06730464","Image-Based Prediction of Ventricular Tachycardia Events in Non-ischemic Cardiomyopathy","Image-Based Prediction of Ventricular Tachycardia Events in Non-ischemic Cardiomyopathy, an International Multicenter Study - [The IMPROVE-NICM Study]","IMPROVE-NICM","Inclusion Criteria:\n\n* Diagnosis of non-ischemic heart disease involving the left ventricle, irrespectively of LVEF. This diagnosis includes:\n\n  1. Dilated cardiomyopathy (DCM)\n  2. Non-dilated left ventricular cardiomyopathy (NDLVC)\n  3. Post-myocarditis cardiomyopathy\n* Life expectancy of \\> 1 year with a good functional status.\n* Signed informed consent.\n* At least one late gadolinium enhancement-cardiac magnetic resonance (LGE-CMR) already performed.\n* No VA events at the time of the 1st LGE-CMR study.\n\nExclusion Criteria:\n\n* Pregnancy.\n* Life expectancy of \\\u003C 1 year, or bad functional status (NYHA IV functional class).\n* Other concomitant structural heart diseases (e.g. ischemic, congenital, arrhythmogenic right ventricular cardiomyopathy etc.)\n* No LGE-CMR at time of enrollment or LGE-CMR data not available.\n* Previously documented sustained ventricular arrhythmias at the time of 1st LGE-CMR.\n* Concomitant investigation treatments.\n* Medical, geographical and social factors that make study participation impractical, and inability to give written informed consent. Patient's refusal to participate in the study.",{"count":64,"type":20},"2 Years","Risk stratification for sudden cardiac death (SCD) in patients with non-ischemic cardiomyopathy (NICM) remains suboptimal. Although current guidelines rely on severe left ventricular systolic dysfunction (left ventricular ejection fraction (LVEF) \\\u003C 35%) as key predictor of arrhythmic risk and clinical indication of prophylactic implantable cardioverter defibrillator (ICD), this approach seems inadequate, since registries report that only a minority of NICM ICD carriers experience an appropriate ICD shock during follow-up, whereas out-of-hospital cardiac arrests (OHCA) occur in patients with LVEF\\>35% in up to 80% of cases. Moreover, pivotal primary prevention trials (DANISH trial, long-term outcome of the SCD-HeFT trial) failed to demonstrate a net mortality benefit of ICD in patients with NICM.\n\nAs for most structural heart diseases (SHD), scar-related reentry has been addressed as the pathophysiological mechanism of ventricular arrhythmias (VAs) in patients with NICM, with fibrotic tissue being the substrate of this reentry. Late gadolinium enhancement cardiac magnetic resonance (LGE-CMR) is the gold standard for the non-invasive visualization and characterization of the myocardial fibrosis and according to retrospective studies is detected in nearly 30% of patients with NICM.\n\nIn latest years, several studies and subsequent metanalyses have explored the correlation between CMR-detected LGE and occurrence of VAs, showing that presence, extent, location (septal vs lateral) and patten (focal vs multifocal vs ring-like) of non-ischemic fibrosis help in stratifying arrhythmic risk.\n\nNonetheless, scar heterogeneity (that is, inherent composition of dense scars vs border zone (BZ), presence of strands of viable myocardium within the scar) has been indicated as a potential novel predictor of VAs. In a recent prospective multicenter registry on patients with class I indication for cardiac resynchronization therapy (CRT) (\\>60% with NICM), not only scar mass, but even border zone (BZ) mass and presence of BZ channels were identified as independent predictors for VT occurrence in NICM patients.\n\nThis BZ mass and BZ channels can be automatically identified using a commercially available, post-processing imaging platform named ADAS 3D LV (ADAS3D Medical SL, Barcelona, Spain), with FDA 510(k) Clearance and CE Mark approval. Thus, CMR-derived BZ mass might be used as an automatically reproducible criterium to reclassify those patients with NICM at highest risk for developing VAs\u002FSCD in a relatively short period of at least 2 years.\n\nIn the present cohort study, the investigators sought to: i) evaluate the usefulness of CMR-derived BZ mass measurement and identification of heterogeneous tissue channels (HTC) (among other scar characteristics derived from image post-processing) to predict the occurrence of VT events in an international, retrospective, multicenter, unselected series of patients with NICM without previous arrhythmia evidence (main study); ii) subsequently validate these predictors of VT occurrence in a prospectively-collected multicenter cohort study (substudy 1); iii) retrospectively evaluate in the subset of patients with \\> 1 LGE-CMR performed as part of standard clinical practice if any change in BZ mass and HTC presence occurs over time and if this correlates with occurrence of VAs (substudy 2).",[300,301,26,302],"Dilated Cardiomyopathy","Arrhythmogenic Cardiomyopathy","Hypertrophic Cardiomyopathies",[304,305,306,307],"Dilated cardiomyopathy","Non-dilated left ventricular cardiomyopathy (NDLVC)","border zone channels","ventricular arrhythmias","2024-12-08",{"date":310,"type":45},"2024-12-12",{"date":312,"type":45},"2024-10-07",{"date":314,"type":20},"2027-02-23",{"name":316,"class":52},"Centro Medico Teknon",4,{"id":319,"slug":320,"hasResults":11,"nctId":321,"briefTitle":322,"officialTitle":323,"acronym":324,"eligibilityCriteria":325,"healthyVolunteers":11,"sex":17,"minAge":62,"maxAge":4,"enrollmentInfo":326,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":328,"conditions":329,"keywords":331,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":308,"lastUpdatePostDateStruct":335,"startDateStruct":336,"completionDateStruct":338,"leadSponsor":340,"locationsCount":226},"100572233","image-based-prediction-of-ventricular-tachycardias-in-post-myocarditis-patients-an-international-multicenter-case-control-study-100572233","NCT06730607","Image-Based Prediction of Ventricular Tachycardias in Post-Myocarditis Patients: an International Multicenter Case-control Study","Image-Based Prediction of Ventricular Tachycardia Events in Post-Myocarditis Patients: an International Multicenter Case-control Study","MYOCARDITIS-VT","Inclusion Criteria:\n\n1. Age \\> 18 years.\n2. Myocarditis diagnosis \\> 6 months before the inclusion in the study.\n3. Signed informed consent.\n4. CMR performed \\> 6 months after myocarditis diagnosis\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years.\n* Pregnancy.\n* Other concomitant structural heart diseases (e.g. congenital, non-ischemic, etc.)\n* Active myocarditis\n* Myocarditis diagnosis \\\u003C 6 months\n* Previously documented sustained ventricular arrhythmias.\n* Impossibility or contraindications to undergo LGE-CMR.\n* Concomitant investigation treatments.\n* Medical, geographical and social factors that make study participation impractical, and inability to give written informed consent. Patient's refusal to participate in the study.",{"count":327,"type":20},150,"Ventricular arrhythmias (VAs) are frequently associated with structural heart diseases (SHD) such as myocardial infarction, myocarditis, and non-ischemic cardiomyopathies. Myocardial fibrotic tissue plays a central role in the genesis and the maintenance of re-entrant VAs associated with post-myocarditis sequelae and late gadolinium enhancement cardiac magnetic resonance (LGE-CMR) has proven to be a useful tool for the non-invasive characterization of the scarred tissue and the underlying arrhythmogenic substrate. Moreover, a post-processing imaging platform named ADAS 3D LV (ADAS3D Medical SL, Barcelona, Spain) allows to analyze the CMR-derived data and to characterize the scar architecture, differentiating between dense (scar core zone) and more diffuse (border zone \\[BZ\\]) fibrosis, and identifying the BZ channels (BZCs) that are strands of healthy myocardial tissue within zones of unexcitable tissue and connect areas of normal myocardium. It was described that BZCs could serve as slow-conducting reentrant pathways and are critical to entail VA in ischemic and non-ischemic heart disease. However, the pathophysiological role and the correlation between scar architecture and VAs in post-myocarditis patients is yet to be defined.\n\nTo date, the standard-of-care evaluation for primary prevention implantable cardioverter-defibrillator (ICD) therapy is LVEF-based, leading to the fact that the contemporary rate of appropriated therapies is very low. Moreover, events may also occur in patients with normal to moderately depressed LVEF, which is particularly relevant, as it constitutes the most prevalent population of patients exposed to an increased risk of VAs. Multiple studies reported that LGE at CMR is a strong and specific predictor of VT occurrence and sudden death in post-myocarditis patients. There were reported cases in which even after the normalization of LVEF, the extension of LGE, the scar architecture, and the presence of BZCs at cMR analysis are determinants of the arrhythmic risk in post-myocarditis patients.\n\nThe Investigators sought to evaluate the usefulness of CMR-derived scar architecture analysis to predict the occurrence of VT events in an international, multicenter, case-control study on unselected post-myocarditis patients without previous arrhythmia evidence. Aim of the study is also to assess the net reclassification improvement (NRI) for the indication of primary prevention ICD implantation using CMR data and post-processing data as compared to LVEF-based indication",[330,26],"Myocarditis",[332,307,333,334],"myocarditis","sudden cardiac death","cardiac magnetic resonance",{"date":310,"type":45},{"date":337,"type":45},"2024-12-02",{"date":339,"type":20},"2026-12-30",{"name":316,"class":52},{"id":342,"slug":343,"hasResults":11,"nctId":344,"briefTitle":345,"officialTitle":346,"acronym":347,"eligibilityCriteria":348,"healthyVolunteers":235,"sex":17,"minAge":349,"maxAge":350,"enrollmentInfo":351,"targetDuration":353,"studyType":22,"phases":4,"briefSummary":354,"conditions":355,"keywords":362,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":378,"lastUpdatePostDateStruct":379,"startDateStruct":381,"completionDateStruct":383,"leadSponsor":385,"locationsCount":53},"100561522","role-of-endomyocardial-biopsy-and-aetiology-based-treatment-in-pediatric-patients-with-inflammatory-heart-disease-in-arrhythmic-and-non-arrhythmic-clinical-presentations-an-integrated-approach-for-the-optimal-diagnostic-and-therapeutic-management-myoped-100561522","NCT06591260","Role of Endomyocardial Biopsy and Aetiology-based Treatment in Pediatric Patients with Inflammatory Heart Disease in Arrhythmic and Non-arrhythmic Clinical Presentations: an Integrated Approach for the Optimal Diagnostic and Therapeutic Management (MYOPED)","Role of Endomyocardial Biopsy and Aetiology-based Treatment in Pediatric Patients with Inflammatory Heart Disease in Arrhythmic and Non-arrhythmic Clinical Presentations: an Integrated Approach for the Optimal Diagnostic and Therapeutic Management","MYOPED","Inclusion Criteria:\n\n* Written informed consent.\n* Age \\< 18 years.\n* Clinically suspected myocarditis.\n* Enrollment performed by one of the participating Centers.\n\nExclusion Criteria:\n\n* Absence of written informed consent.\n* Age \\> 18 years (adults)","0 Years","17 Years",{"count":352,"type":20},20,"30 Years","Myocarditis is a complex inflammatory disease, usually occurring secondary to viral infections, autoimmune processes or toxic agents. Clinical presentations are multiple, including chest-pain, heart failure and a broad spectrum of arrhythmias. In turn, outcome is largely unpredictable, ranging from mild self-limiting disease, to chronic stage and progressive evolution towards dilated cardiomyopathy, to rapid adverse outcome in fulminant forms. Subsequently, myocarditis is often underdiagnosed and undertreated, and optimal diagnostic and therapeutic strategies are still to be defined. This study, both retrospective and prospective, originally single-center and subsequently upgraded to multicenter, aims at answering multiple questions about myocarditis, with special attention to its arrhythmic manifestations.\n\nOptimal diagnostic workflow is still to be defined. In fact, although endomyocardial biopsy (EMB) is still the diagnostic gold standard, especially for aetiology identification, it is an invasive technique. Furthermore, it may lack sensitivity because of sampling errors. By converse, modern imaging techniques - cardiac magnetic resonance (CMR) in particular - have been proposed as alternative or complementary diagnostic tool in inflammatory heart disease. Other noninvasive diagnostic techniques, like delayed-enhanced CT (DECT) scan or position emission tomography (PET) scan, are under investigation.\n\nBiomarkers to identify myocarditis aetiology, predisposition, prognosis and response to treatment are still to be defined.\n\nArrhythmic myocarditis is largely underdiagnosed and uninvestigated. Importantly, myocarditis presenting with arrhythmias requires specific diagnostic, prognostic and therapeutic considerations. At the group leader hospital, which is an international referral center for ventricular arrhythmias management and ablation, a relevant number of patients with unexplained arrhythmias had myocarditis as underlying aetiology. The experience of a dedicated third-level center is going to be shared with other centers, to considerably improve knowledge and management of arrhythmic myocarditis.\n\nThe role of CMR, as well as alternative noninvasive imaging techniques, in defining myocarditis healing is a relevant issue. In particular, optimal timing for follow-up diagnostic reassessment is still to be defined, in patients with myocarditis at different inflammatory stages, either with or without aetiology-dependent treatment.\n\nUniformly-designed studies are lacking, to compare myocarditis among different patient subgroups, differing by variables like: clinical presentations, myocarditis stage, associated cardiac or extra-cardiac diseases, aetiology-based treatment, associated arrhythmic manifestations, diagnostic workup, and devices or ablation treatment.",[330,26,356,357,358,359,211,360,361],"Inflammatory Cardiomyopathy","Genetic Predisposition","Autoimmunity","Arrhythmia","Immunosuppresion","Catheter Ablation",[330,363,364,365,366,367,368,369,370,371,372,373,374,375,376,377],"Ventricular arrhythmias","Arrhythmias","Arrhythmogenic inflammatory cardiomyopathy","Endomyocardial biopsy","Cardiac magnetic resonance","Ablation","Positron emission tomography","Electroanatomical mapping","Immunosuppressive therapy","Arrhythmic risk stratification","Genetic predisposition","Environment","Implantable cardioverter defibrillator","Implantable loop recorder","Multicenter","2024-09-11",{"date":380,"type":45},"2024-09-19",{"date":382,"type":45},"2013-01-01",{"date":384,"type":20},"2030-12-31",{"name":386,"class":52},"Scientific Institute San Raffaele",{"id":388,"slug":389,"hasResults":11,"nctId":390,"briefTitle":391,"officialTitle":391,"acronym":4,"eligibilityCriteria":392,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":393,"targetDuration":395,"studyType":22,"phases":4,"briefSummary":396,"conditions":397,"keywords":4,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":402,"lastUpdatePostDateStruct":403,"startDateStruct":405,"completionDateStruct":407,"leadSponsor":409,"locationsCount":53},"100209121","implantable-cardioverter-defibrillator-icd-registry-100209121","NCT01999140","Implantable Cardioverter Defibrillator (ICD Registry)","All U.S and International patients.\n\nInclusion Criteria:\n\n* All patients who receive an ICD\u002FCRT-D (initial or generator change) for primary or secondary prevention purposes.\n* All patients with an ICD\u002FCRT-D undergoing a Lead Only procedure.\n* U.S. populations must submit all patients who receive an ICD\u002FCRT-D (initial or generator change) for primary prevention purposes who are insured by Medicare.\n\nExclusion Criteria:\n\nNone",{"count":394,"type":20},1750,"1 Day","The ICD Registry™ is a nationwide quality program that helps participating hospitals measure and improve care for patients receiving implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy devices with defibrillator (CRT-Ds). The ICD Registry captures the characteristics, treatments, and outcomes of patients receiving (ICDs). Patient-level data is submitted by participating hospitals on a quarterly basis to the American College of Cardiology Foundation's (ACCF) National Cardiovascular Data Registry (NCDR) which then produces an Outcomes Report of the hospital's data, with comparison to both a volume peer group (number of ICD patients submitted annually) and the entire ICD registry data set.",[398,399,400,26,401],"Heart Failure","Nonischemic Cardiomyopathy","Ischemic Cardiomyopathy","Complications; Device, Cardiac","2024-04-17",{"date":404,"type":45},"2024-04-18",{"date":406,"type":4},"2005-06",{"date":408,"type":20},"2030-06",{"name":410,"class":52},"American College of Cardiology"]